Exact Sciences (EXAS) closed the last trading day at $67.92, down 0.67% from the previous trading session. The move was smaller than the S&P 500's 1.56% decline for the day. Elsewhere, the Dow lost 1.81% while the Tech-Nasdaq lost 4.66%.
The molecular diagnostics company's shares were up 33.84% month-on-month today. Meanwhile, the medical sector was up 0.86% and the S&P 500 was up 3.82%.
Investors are looking to Exact Science for strength as it heads into its next earnings report. In this report, analysts expect Exact Sciences to report earnings of -$0.92 per share. It will grow by 28.13% per year. Meanwhile, our latest agreed estimate was revenue of $527.13 million, up 11.25% from the year-ago quarter.
Investors should also pay attention to recent changes in analyst forecasts for the exact sciences. The recent correction reflects the recent short term trading trend. Thus, the positive revision of the forecast reflects analysts' optimism about the company's business and profitability.
Based on our research, we believe this rework is directly related to the team's inventory movement. We took advantage of this phenomenon and created Zacks Rank. Our system takes these changing assumptions into account and provides a clear and efficient scoring model.
Ranging from #1 (strong buy) to #5 (strong sell), the Zacks Rating system has an impressive track record, backed by external audits, with the #1 stock up +25% since 1988 Earning a CAGR. Last month, Zacks. The consensus EPS estimate is up 4.54%. Exact Science is currently ranked #2 Zack (Buy).
Drug. The biomedical and genetic industries are part of the medical sector. The industry currently has a Zacks 70 industry rating, placing it in the top 28% of 250+ industries.
Zacks Industry Ratings evaluates the strength of our industry group by measuring the average Zacks rating of each stock in the group. Our research shows that the top 50% of the industry outperforms the bottom by a factor of 2 to 1.
For more information on all of these metrics and more, visit Zacks.com.
To read this article on Zacks.com, click here.